LEO Pharma

LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day


BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis.

The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis:


The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com

The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases.

October 2020 marks the second year of a three-year ‘Connected, Informed, United’ IFPAtheme, with the theme of ‘Be Informed’ the focus of this year.

Henrik Kyndlev, Director of Global External Communications at LEO Pharma, said: “We’re proud to support IFPA’s important initiative, and are keen to do our part in helping people ‘Be Informed’ about psoriasis this year.”

“Our campaign supports this theme in a very simple but powerful way - namely by bringing attention to some everyday psoriasis stories of real-life patients. After all, psoriasis is not just about a single day, but is an everyday challenge for many patients.”

The #everydaypsoriasis campaign centres around three audio-interviews with psoriasis patients, whose stories are brought to life with short animations depicting the everyday challenges they face.

‘Jane’ talks about how the simple, everyday experience of grocery shopping is a challenge, as she feels people are looking at her skin, and think her psoriasis is contagious. Psoriasis is in fact an auto-immune disease and so is not contagious – one of the key messages IFPA want to focus on in 2020.

Watch Jane’s video: click here

‘Steve’ speaks about the sense of futility he sometimes feels because of the cycle of psoriasis flares, and the feeling of going through a “revolving door”.

Watch Steve’s video: click here

‘Becky’ talks about how having psoriasis as a child affected her confidence, and the ongoing challenge she feels now as a young adult.

Watch Becky’s video: click here

Alexandre Fevre, Vice President of Global Marketing, Psoriasis, at LEO Pharma, said of the campaign, “For many patients, psoriasis goes beyond just being a cosmetic challenge. Nearly 60 percent1 of people with psoriasis say their disease is a large problem in their everyday life.”

“This campaign draws attention to some of the everyday psoriasis challenges and gives a voice to psoriasis patients. We also hope it demonstrates LEO Pharma’s continued commitment to helping people achieve healthy skin.”

“As we say on our campaign website, the encouraging news for many patients is that there are ways to manage the condition. Not just treatments, but lifestyle changes too. If you or someone you know is experiencing #everydaypsoriasis challenges, consider approaching your doctor for advice.”

The #everydaypsoriasis videos can be viewed at www.everydaypsoriasis.com.

About psoriasis

Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide.1,2 About 80% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis.2 The symptoms of plaque psoriasis are itchy or painful, scaly, inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso.3 Psoriasis is characterized as mild when less than 3% of the body is affected and moderate to severe when more than 3% of the body is affected.4


1. Stern RS, et al. J Investig Dermatol Symp Proc. 2004;9(2):136-9.
2. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
3. Menter A et al. J Am Acad Dermatol 2008;58:826.
4. Armstrong AW et al. JAMA Dermatol. 2013;149(10):1180–1185.

Our Manifesto Video


Henrik Kyndlev
+45 3140 6180

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development16.12.2020 12:15:37 CETPress release

Ballerup, December 16, 2020 – LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee. A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with exte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom